F30-F39 F20-F29
Conditions
Interventions
Group 1: Patients receiving ECT treatment receive the following examinations:
Before ECT series: Blood sampling (CRP, TSH, fT3, fT4, TAK, TRAK, MAK, thyroglobulin, DHEA, DHEAS, cholesterol, triglyceri
Sponsors
Medizinische Hochschule Hannover
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Patients with ECT treatment (ICD-10 F20.-, F30-F39) - Patients with major depression who are currently receiving no antidepressant drug treatment, as well as - healthy control subjects without previous psychiatric illness - Age = 18 years - male and female patients - Treatment in a study center - Signed informed consent of the patient or his legal guardian
Exclusion criteria
Exclusion criteria: - Simultaneous participation in another clinical trial - Missing consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Remission after 12 ECT treatments Remission defined as MADRS Score <10 or PANSS-Score <59 | — |
Secondary
| Measure | Time frame |
|---|---|
| - Time to Response (Response: 50% reduction of the initial value in the self- and external rating scales BDI, MADRS, PANSS); Time to remission (remission: BDI Score <13, MADRS Score <10, PANSS Score <59) - Analysis of established and new quality standards of treatment (eg postictal suppression index, EEG, frequency and intensity of stimulus, peak heart rate, co-medication, narcosis) - Recording of adverse effects of treatment (Mini-Mental Status Exam, Adverse Events) - Molecular biological risk factor analysis focusing on neurotrophic (e.g., BDNF, VEGF, GDNF) and immunological (e.g., TNF-alpha, IL-6, Tpa, S100A10) factors (expression, epigenetic studies) to analyze predictive factors for outcome | — |
Countries
Germany
Contacts
Public ContactHannah Maier
Medizinische Hochschule Hannover
Outcome results
None listed